Zacks Investment Research upgraded shares of Mazor Robotics (NASDAQ:MZOR) from a hold rating to a buy rating in a research note released on Friday. Zacks Investment Research currently has $67.00 price objective on the medical instruments supplier’s stock.
According to Zacks, “Mazor Robotics Ltd. is engaged in the development, production and marketing of medical devices for surgical procedures in the fields of orthopedics and neurosurgery. It offers Renaissance(TM), a surgical robotic system to conduct spine surgeries with less radiation. The company operates in the United States, Eastern Europe, Western Europe and Asia. Mazor Robotics Ltd. is based in Caesarea, Israel. “
A number of other research analysts also recently weighed in on the stock. Needham & Company LLC restated a hold rating on shares of Mazor Robotics in a report on Wednesday, February 14th. BidaskClub upgraded shares of Mazor Robotics from a hold rating to a buy rating in a report on Friday, February 2nd. Barclays reiterated a sell rating and issued a $36.00 target price on shares of Mazor Robotics in a report on Tuesday, January 9th. TheStreet upgraded shares of Mazor Robotics from a d rating to a c- rating in a report on Wednesday, November 8th. Finally, Ladenburg Thalmann Financial Services set a $67.00 target price on shares of Mazor Robotics and gave the stock a buy rating in a report on Monday, October 30th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating to the company. The company has an average rating of Hold and an average price target of $44.50.
Mazor Robotics (NASDAQ:MZOR) last released its quarterly earnings results on Wednesday, February 14th. The medical instruments supplier reported $0.02 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.09. The business had revenue of $19.15 million for the quarter, compared to the consensus estimate of $19.00 million. Mazor Robotics had a negative net margin of 19.08% and a negative return on equity of 14.03%. Mazor Robotics’s revenue for the quarter was up 36.4% on a year-over-year basis. During the same quarter last year, the firm earned ($0.07) EPS. equities analysts forecast that Mazor Robotics will post 0.06 earnings per share for the current year.
A number of institutional investors and hedge funds have recently made changes to their positions in MZOR. Global X Management Co. LLC raised its holdings in Mazor Robotics by 127.8% in the 4th quarter. Global X Management Co. LLC now owns 263,147 shares of the medical instruments supplier’s stock worth $13,578,000 after acquiring an additional 147,611 shares during the period. Sumitomo Mitsui Trust Holdings Inc. bought a new position in Mazor Robotics in the 3rd quarter worth $6,371,000. Global X MANAGEMENT CO LLC raised its holdings in Mazor Robotics by 5,758.8% in the 3rd quarter. Global X MANAGEMENT CO LLC now owns 115,536 shares of the medical instruments supplier’s stock worth $5,704,000 after acquiring an additional 113,564 shares during the period. Crawford Lake Capital Management LLC bought a new position in Mazor Robotics in the 3rd quarter worth $4,554,000. Finally, Dorsey Wright & Associates bought a new position in Mazor Robotics in the 3rd quarter worth $4,537,000. Hedge funds and other institutional investors own 26.42% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was first posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://www.chaffeybreeze.com/2018/02/20/mazor-robotics-mzor-upgraded-to-buy-at-zacks-investment-research.html.
Mazor Robotics Company Profile
Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mazor Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics and related companies with MarketBeat.com's FREE daily email newsletter.